Genmab A/S
Toldbodgade 33
1253 Copenhagen K
Denmark
Tel + 45 7020 2728
Fax + 45 7020 2729
CVR no. 2102 3884

Contact:

Helle Husted
Sr. Director, Investor Relations
T: +45 33 44 77 30
M: +45 25 27 47 13
E: hth@genmab.com

PASSING OF GENMAB A/S' ANNUAL GENERAL MEETING

Summary: At Genmab A/S' Annual General Meeting held today on April 19, 2007 the Annual Report for 2006 was approved, discharge was given to the Board of Directors and the Management and the year's loss was carried forward. One member of the Board of Directors was re-elected and two new members were elected. PricewaterhouseCoopers was re-elected as auditor of the Company. The proposals from the Board of Directors to change the Articles of Association and authorization to allow the Company to purchase shares in the Company were adopted.

Copenhagen, Denmark; April 19, 2007 – Genmab A/S (CSE: GEN) held its Annual General Meeting, today April 19, 2007 at 2:00 pm at Radisson SAS Royal Hotel, Hamerichsgade 1, 1611 Copenhagen, Denmark.

At the meeting Chairman of the Board Dr. Michael B. Widmer gave – on behalf of the Board – a report on the Company's activities during the past year. Chief Executive Officer and member of the Board, Lisa N. Drakeman presented plans for the year ahead, and Chief Financial Officer Bo Kruse presented the Annual Report for 2006 endorsed by the auditors. The report was approved and discharge was given to the Board and the Management.

It was decided that the year's loss of DKK 438 million be carried forward by transfer to accumulated deficit, as stated in the Annual Report.

Dr. Anders Gersel Pedersen was re-elected to the Board for a further three year period. Dr. Burton G. Malkiel and Hans Henrik Munch-Jensen were elected to the Board for a period of three and two years respectively.

PricewaterhouseCoopers (State Authorized Accountants) was reelected as the Company's auditor.

PASSING OF GENMAB A/S' ANNUAL GENERAL MEETING

The General Meeting adopted the proposals from the Board to change the Company's Articles of Association, as follows:

- The proposal to amend Article 4A of the Articles of Association, authorizing the Board of Directors to issue new shares, so that the authorization is increased from nominally DKK 10,528,798 shares to nominally DKK 15,000,000 shares and it is prolonged to apply for 5 years from this General Meeting, and so that within the 15,000,000 shares the Board may issue up to nominally DKK 2,000,000 shares (including bonus shares) to employees of the Company and its subsidiaries.

- The proposal to amend Article 6A to authorize the Board of Directors to issue additional warrants – without pre-emption rights for the existing shareholders - that give the right to subscribe up to nominally DKK 1,000,000 shares in the Company to members of the Company's Board of Directors, the Company's employees and consultants as well as employees and consultants of the Company's subsidiaries and to implement the corresponding capital increases related to the warrants issued.

- The proposal to amend Article 7 section one of the Articles of Association as a consequence of VP Investor Service A/S's acquisition of the shareholder registry activities from Danske Bank A/S.

- The proposal to amend Article 9 section 4 of the Articles of Association as a consequence of a change of the Danish Companies Act under which it is required that callings for the Company's general meetings are published in the computer information system of the Danish Commerce and Companies Agency.

- The proposal to amend Article 18 of the Articles of Association to reflect the Company's application of the current accounting regulations.

Finally the Board of Directors were authorized according to Section 48 of the Danish Companies Act so that until the next Annual General Meeting the Company may purchase own shares in connection with the buy-back of shares subscribed by employees etc. pursuant to the Company's employee warrant programmes to the extent of up to 2 percent of the Company's share capital and so that the consideration for such shares shall be equal to the exercise price paid for the shares in question.

About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb® platform for the rapid creation and development of human antibodies to virtually any disease target. In addition, Genmab has

developed UniBody™, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. For more information about Genmab, visit www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

###